Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Time Factors MeSH
- Central Nervous System drug effects metabolism MeSH
- Blood-Brain Barrier drug effects metabolism MeSH
- Rats MeSH
- Brain drug effects metabolism MeSH
- Oximes metabolism pharmacokinetics MeSH
- Rats, Wistar MeSH
- Pyridinium Compounds metabolism pharmacokinetics MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide MeSH Browser
- Oximes MeSH
- Pyridinium Compounds MeSH
The blood-brain barrier plays a vital role in the protection of the central nervous system. It is composed of endothelial cells with tight-junctions to limit the penetration of many endogenous and exogenous compounds, particularly hydrophilic xenobiotics. Nerve agents and pesticides are groups of compounds with high penetration potential into the central nervous system. However, oxime type antidotes are known to penetrate blood-brain barrier only in low concentration. The aim of presented study is to describe the pharmacokinetic profile of oxime K027 a novel antidote candidate. The main focus is on penetration of tested substance into the selected brain regions following time-dependent manner. The maximum concentration of the oxime K027 was attaining 15 and 30 min after i.m. application in plasma and brain tissue, respectively. The perfused brain tissue concentration was relatively high (10(-7) M order of magnitude) and depending on the brain region it was constant 15-60 min after application. The highest concentration was found in the frontal cortex 15 min after application while the lowest measured concentration was determined in the basal ganglia. This study showed that oxime K027 is able to achieve high concentration level in perfused brain tissue relatively quickly, but also demonstrated rapid clearance from the central nervous system. These results are probably due to low overall uptake of oxime K027 into the brain.
See more in PubMed
Mini Rev Med Chem. 2008 Oct;8(11):1134-43 PubMed
Chem Biol Interact. 2010 Sep 6;187(1-3):199-206 PubMed
J Appl Toxicol. 2013 Jan;33(1):18-23 PubMed
Toxicol Mech Methods. 2007;17(7):401-8 PubMed
Chem Biol Interact. 2008 Sep 25;175(1-3):281-5 PubMed
Curr Med Chem. 2008;15(8):743-53 PubMed
Sensors (Basel). 2009;9(5):3627-34 PubMed
Curr Drug Metab. 2002 Dec;3(6):647-57 PubMed
Chem Biol Interact. 2010 Sep 6;187(1-3):287-90 PubMed
Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):195-209 PubMed
Behav Brain Res. 2009 Nov 5;203(2):207-14 PubMed
Bioorg Med Chem Lett. 2003 Oct 20;13(20):3545-7 PubMed
J Appl Toxicol. 2007 Jul-Aug;27(4):350-7 PubMed
J Pharm Biomed Anal. 2010 Aug 1;52(4):508-16 PubMed
Neurochem Res. 2003 Sep;28(9):1401-7 PubMed
Pharm Res. 2007 Sep;24(9):1729-32 PubMed
J Enzyme Inhib Med Chem. 2010 Aug;25(4):480-4 PubMed
J Enzyme Inhib Med Chem. 2010 Aug;25(4):509-12 PubMed
Prog Neurobiol. 2005 May;76(1):22-76 PubMed
Curr Med Chem. 2010;17(12):1125-38 PubMed
J Chromatogr A. 2007 Aug 17;1161(1-2):146-51 PubMed
Pharm Res. 2007 Sep;24(9):1745-58 PubMed
Chem Biol Interact. 2007 Jan 5;165(1):14-21 PubMed
J Pharm Biomed Anal. 2011 Apr 5;54(5):1082-7 PubMed
J Med Chem. 2004 Dec 2;47(25):6338-48 PubMed
Brominated oxime nucleophiles are efficiently reactivating cholinesterases inhibited by nerve agents
Development of versatile and potent monoquaternary reactivators of acetylcholinesterase
